AlphAIalphai — Financial news for AI agents
Simply Wall StreetMAY 113 min read$CDXS

US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results

Analysts have re-evaluated Codexis, Inc. (CDXS) after its latest quarterly results, which showed stronger-than-expected revenues of US$15m and lower losses per share at US$0.10. Despite an improved sentiment regarding future losses, the consensus price target has been reduced by 7.1% to US$6.58 due to ongoing profitability concerns and an anticipated revenue decline of 5.0% in 2026, contrasting with industry growth.

Original reporting
Simply Wall Street · Simply Wall St
Published May 11, 2026, 12:03 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 11, 2026, 12:31 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
US$6.58: That's What Analysts Think Codexis, Inc. (NASDAQ:CDXS) Is Worth After Its Latest Results — source image
Source · Simply Wall Street
Decision brief

The 30-second read

$CDXSNeutralMed
01

Why it matters

Despite revenue strength, ongoing profitability issues and revenue decline forecasts have led analysts to lower their price targets, creating a cautious outlook.

02

Market read

The news primarily impacts investors and traders focusing on biotech stocks, especially those with recent earnings reports and profitability concerns.

03

What to watch

Potential upcoming catalysts such as new product launches or strategic partnerships that could offset profitability concerns and support stock recovery.

Timing: short-term (next 1-3 months)

Background

Codexis, Inc. reported quarterly revenues of US$15 million with losses per share reduced to US$0.10, indicating operational improvements.

Company-level read

Ticker impact

$CDXSNeutralMedium confidence
Context

Primary focus of the news, as it discusses recent analyst evaluations and future outlook.

Expected impact

Potential short-term price decline of approximately 5-7%, aligning with the reduction in target price and profitability worries.

Evidence & confidence

The analysis is based on recent earnings data and analyst revisions, but market reactions can be influenced by broader factors and investor sentiment.

Market effects

Sector

Potential cautious sentiment in the biotech and pharmaceutical sectors due to profitability concerns.

Regional

Limited; primarily affects US-based biotech stocks.

Global

Low; specific to company and sector, with minimal global market impact.

Counterpoint

What could challenge this read

The strong revenue performance and reduced losses may signal underlying operational improvements, potentially leading to a positive re-evaluation by the market in the medium term.

Key entities

  • Company
    Codexis, Inc.

    A biotechnology company focusing on enzyme engineering and biocatalysis.

  • Market Participants
    Analysts

    Financial analysts revising target prices based on recent earnings.

Read at source← All news

Related articles

AUG 19
$CDXSMedAI 8/10

Codexis (CDXS) Q2 2026 Earnings Call Transcript

Codexis (CDXS) reported Q2 2026 revenue of $14.9M, down from $15.3M in Q2 2025. Product revenue rose to $13.2M, while R&D revenue fell to $1.7M. Net loss narrowed to $12.0M. The company guided full-year revenue to $72M-$76M and maintained a high 60% gross margin target. It plans to invest $25M in a GMP facility and expects a 30-fold increase in siRNA market demand by 2035. CDXS has 14 commercial products and 15 clinical programs in Phase II/III. Management highlighted progress in ECOsynthesis pl

fool.com6 min
AUG 11
$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma

SEC EDGAR 8-K6 min
JUL 23
$CDXSMed

CODEXIS, INC. (CDXS): Results of Operations and Financial Condition

CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. 8-K false 0001200375 0001200375 2026-07-23 2026-07-23 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 23,

SEC EDGAR 8-K2 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min